TY - STD TI - Sexually transmitted diseases treatment guidelines. 2010. [http://www.cdc.gov/std/treatment/2010/hepC.htm]. Accessed 19 Sep 2013. UR - http://www.cdc.gov/std/treatment/2010/hepC.htm ID - ref1 ER - TY - STD TI - Hepatitis C FAQs for Health Professionals. [http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm]. Accessed 19 Sep 2013. UR - http://www.cdc.gov/hepatitis/HCV/HCVfaq.htm ID - ref2 ER - TY - JOUR AU - Moyer, V. A. PY - 2013 DA - 2013// TI - Screening for hepatitis C virus infection in adults: US Preventive Services Task Force Recommendation Statement JO - Ann Intern Med VL - 159 ID - Moyer2013 ER - TY - JOUR AU - Klevens, R. M. AU - Hu, D. J. AU - Jiles, R. AU - Holmberg, S. D. PY - 2012 DA - 2012// TI - Evolving epidemiology of hepatitis C virus in the United States JO - Clin Infect Dis VL - 55 UR - https://doi.org/10.1093/cid/cis393 DO - 10.1093/cid/cis393 ID - Klevens2012 ER - TY - JOUR AU - Blatt, L. M. AU - Mutchnick, M. G. AU - Tong, M. J. AU - Klion, F. M. AU - Lebovics, E. AU - Freilich, B. AU - Bach, N. AU - Smith, C. AU - Herrera, J. AU - Tobias, H. PY - 2000 DA - 2000// TI - Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States JO - J Viral Hepat VL - 7 UR - https://doi.org/10.1046/j.1365-2893.2000.00221.x DO - 10.1046/j.1365-2893.2000.00221.x ID - Blatt2000 ER - TY - JOUR AU - Spradling, P. R. AU - Rupp, L. AU - Moorman, A. C. AU - Lu, M. AU - Teshale, E. H. AU - Gordon, S. C. AU - Nakasato, C. AU - Boscarino, J. A. AU - Henkle, E. M. AU - Nerenz, D. R. PY - 2012 DA - 2012// TI - Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence JO - Clin Infect Dis VL - 55 UR - https://doi.org/10.1093/cid/cis616 DO - 10.1093/cid/cis616 ID - Spradling2012 ER - TY - JOUR AU - Hagan, H. AU - Campbell, J. AU - Thiede, H. AU - Strathdee, S. AU - Ouellet, L. AU - Kapadia, F. AU - Hudson, S. AU - Garfein, R. S. PY - 2006 DA - 2006// TI - Self-reported hepatitis C virus antibody status and risk behavior in young injectors JO - Public Health Rep VL - 121 ID - Hagan2006 ER - TY - JOUR AU - Afdhal, N. H. PY - 2004 DA - 2004// TI - The natural history of hepatitis C JO - Semin Liver Dis VL - 24 UR - https://doi.org/10.1055/s-2004-832922 DO - 10.1055/s-2004-832922 ID - Afdhal2004 ER - TY - STD TI - Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010; 138:513–521, 521 e511–516. ID - ref9 ER - TY - JOUR AU - Ghany, M. G. AU - Strader, D. B. AU - Thomas, D. L. AU - Seeff, L. B. PY - 2009 DA - 2009// TI - Diagnosis, management, and treatment of hepatitis C: an update JO - Hepatology VL - 49 UR - https://doi.org/10.1002/hep.22759 DO - 10.1002/hep.22759 ID - Ghany2009 ER - TY - STD TI - American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Monitoring patients who are starting hepatitis C treatment, are on treatment, or have completed therapy. In: Recommendations for testing, managing, and treating Hepatitis C. 2014. [http://www.hcvguidelines.org/full-report-view]. Accessed 16 March 2015. UR - http://www.hcvguidelines.org/full-report-view ID - ref11 ER - TY - STD TI - European Public Assessment Report. PegIntron [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000280/WC500039388.pdf]. Accessed 7 Feb 2014. UR - http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000280/WC500039388.pdf ID - ref12 ER - TY - STD TI - Biologics License Application Supplement: PEGASYS. [http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/pegihof120302LB.htm#desc]. Accessed 7 Feb 2014. UR - http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/pegihof120302LB.htm%23desc ID - ref13 ER - TY - JOUR AU - Ghany, M. G. AU - Nelson, D. R. AU - Strader, D. B. AU - Thomas, D. L. AU - Seeff, L. B. PY - 2011 DA - 2011// TI - An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases JO - Hepatology VL - 54 UR - https://doi.org/10.1002/hep.24641 DO - 10.1002/hep.24641 ID - Ghany2011 ER - TY - STD TI - DailyMed: Current medication information. [http://dailymed.nlm.nih.gov/dailymed]. Accessed 31 July 2014. UR - http://dailymed.nlm.nih.gov/dailymed ID - ref15 ER - TY - JOUR AU - Fried, M. W. AU - Shiffman, M. L. AU - Reddy, K. R. AU - Smith, C. AU - Marinos, G. AU - Goncales, F. L. AU - Haussinger, D. AU - Diago, M. AU - Carosi, G. AU - Dhumeaux, D. PY - 2002 DA - 2002// TI - Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection JO - N Engl J Med VL - 347 UR - https://doi.org/10.1056/NEJMoa020047 DO - 10.1056/NEJMoa020047 ID - Fried2002 ER - TY - JOUR AU - Manns, M. P. AU - McHutchison, J. G. AU - Gordon, S. C. AU - Rustgi, V. K. AU - Shiffman, M. AU - Reindollar, R. AU - Goodman, Z. D. AU - Koury, K. AU - Ling, M. AU - Albrecht, J. K. PY - 2001 DA - 2001// TI - Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial JO - Lancet VL - 358 UR - https://doi.org/10.1016/S0140-6736(01)06102-5 DO - 10.1016/S0140-6736(01)06102-5 ID - Manns2001 ER - TY - JOUR AU - Younossi, Z. M. AU - Singer, M. E. AU - Mir, H. M. AU - Henry, L. AU - Hunt, S. PY - 2014 DA - 2014// TI - Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients JO - J Hepatol VL - 60 UR - https://doi.org/10.1016/j.jhep.2013.11.009 DO - 10.1016/j.jhep.2013.11.009 ID - Younossi2014 ER - TY - STD TI - New guidelines expected to help clinicians sort out hepatitis C treatment options. [http://newsatjama.jama.com/2014/01/30/new-guidelines-expected-to-help-clinicians-sort-out-hepatitis-c-treatment-options/]. Accessed 31 July 2014. UR - http://newsatjama.jama.com/2014/01/30/new-guidelines-expected-to-help-clinicians-sort-out-hepatitis-c-treatment-options/ ID - ref19 ER - TY - JOUR AU - Hagan, L. M. AU - Yang, Z. AU - Ehteshami, M. AU - Schinazi, R. F. PY - 2013 DA - 2013// TI - All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses JO - J Viral Hepat VL - 2013 ID - Hagan2013 ER - TY - STD TI - FDA Approves ‘Game Changer’ Hepatitis C Drug Sofosbuvir. [http://www.medscape.com/viewarticle/817371]. Accessed 13 March 2014. UR - http://www.medscape.com/viewarticle/817371 ID - ref21 ER - TY - STD TI - The majority of physicians that treat hepatitis C virus (HCV) have begun “Warehousing” and preparing their HCV patients for the next generation of HCV treatments. [http://bio-trends.com/News-and-Events/Press-Releases/TreatmentTrends-Hepatitis-C-Virus-052313]. Accessed 15 March 2015. UR - http://bio-trends.com/News-and-Events/Press-Releases/TreatmentTrends-Hepatitis-C-Virus-052313 ID - ref22 ER - TY - STD TI - FirstWord Pharma. Physician views: what opportunity for Gilead Sciences’ hepatitis c therapy sofosbuvir before interferon-sparing regimens reach the market? In: Physician Views Desk. 2013. ID - ref23 ER - TY - STD TI - BioTrends Research Group. The majority of physicians that treat hepatitis c virus (HCV) have begun “warehousing” and preparing their HCV patients for the next generation of HCV treatments. 2013. ID - ref24 ER - TY - STD TI - FirstWord Pharma. ViewPoints: Identifying the unidentified—the hepatitis c market and patient warehousing. 2012. ID - ref25 ER - TY - STD TI - Gilead announces US FDA priority review designation for ledipasvir/sofosbuvir fixed-dose combination tablet for chronic hepatitis C genotype 1 infection. [http://www.gilead.com/news/press-releases/2014/4/gilead-announces-us-fda-priority-review-designation-for-ledipasvirsofosbuvir-fixeddose-combination-tablet-for-chronic-hepatitis-c-genotype-1-infection]. Accessed 31 July 2014. UR - http://www.gilead.com/news/press-releases/2014/4/gilead-announces-us-fda-priority-review-designation-for-ledipasvirsofosbuvir-fixeddose-combination-tablet-for-chronic-hepatitis-c-genotype-1-infection ID - ref26 ER - TY - STD TI - McQuillan GM, MD, Denniston MM, Hirsch R. Viral hepatitis. In: NCHS data brief (Statistics NCfH ed. Hyattsville, MD: US. 2010. ID - ref27 ER - TY - STD TI - Viral hepatitis statistics and surveillance. [http://www.cdc.gov/hepatitis/statistics/]. Accessed 30 Nov 2013. UR - http://www.cdc.gov/hepatitis/statistics/ ID - ref28 ER - TY - STD TI - US Census Bureau. 2012 American community survey: 1-year estimate (S0101) using American FactFinder. vol. 2013. ID - ref29 ER - TY - STD TI - US Census Bureau. Population distribution and change: 2000–2010. In: 2010 census briefs. 2011. ID - ref30 ER - TY - STD TI - State and County QuickFacts. District of Columbia. [http://quickfacts.census.gov/qfd/states/11000.html]. Accessed 9 April 2014. UR - http://quickfacts.census.gov/qfd/states/11000.html ID - ref31 ER - TY - STD TI - Resident population data (text version). [http://www.census.gov/2010census/data/apportionment-dens-text.php]. Accessed 9 April 2014. UR - http://www.census.gov/2010census/data/apportionment-dens-text.php ID - ref32 ER - TY - JOUR AU - Moyer, V. A. PY - 2013 DA - 2013// TI - Screening for hepatitis C virus infection in adults: US preventive services task force recommendation statement JO - Ann Intern Med VL - 159 UR - https://doi.org/10.7326/0003-4819-159-5-201309030-00672 DO - 10.7326/0003-4819-159-5-201309030-00672 ID - Moyer2013 ER - TY - JOUR AU - Volk, M. L. AU - Tocco, R. AU - Saini, S. AU - Lok, A. S. PY - 2009 DA - 2009// TI - Public health impact of antiviral therapy for hepatitis C in the United States JO - Hepatology VL - 50 UR - https://doi.org/10.1002/hep.23220 DO - 10.1002/hep.23220 ID - Volk2009 ER - TY - STD TI - Biomed Tracker. Cost of anticipated all oral therapy for genotype 1 chronic hepatitis C virus: sofosbuvir/ledipasvir combination. e-mail communication edition. 2014. ID - ref35 ER - TY - STD TI - Prognosis in decompensated chronic liver failure. Fast facts and concepts. [http://www.eperc.mcw.edu/EPERC/FastFactsIndex/ff_189.htm]. Accessed 25 Sep 2013. UR - http://www.eperc.mcw.edu/EPERC/FastFactsIndex/ff_189.htm ID - ref36 ER - TY - JOUR AU - Manos, M. M. AU - Darbinian, J. AU - Rubin, J. AU - Ray, G. T. AU - Shvachko, V. AU - Denis, B. AU - Velez, F. AU - Quesenberry, C. PY - 2013 DA - 2013// TI - The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting JO - J Manag Care Pharm VL - 19 ID - Manos2013 ER - TY - STD TI - Consumer Price Index. CPI databases: All urban consumers (current series). [http://www.bls.gov/cpi/data.htm]. Accessed 11 Oct 2013. UR - http://www.bls.gov/cpi/data.htm ID - ref38 ER - TY - JOUR AU - Gordon, S. C. AU - Pockros, P. J. AU - Terrault, N. A. AU - Hoop, R. S. AU - Buikema, A. AU - Nerenz, D. AU - Hamzeh, F. M. PY - 2012 DA - 2012// TI - Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection JO - Hepatology VL - 56 UR - https://doi.org/10.1002/hep.25842 DO - 10.1002/hep.25842 ID - Gordon2012 ER - TY - STD TI - Centers for Medicare and Medicaid Services: NHE Projections 2012–2022. ID - ref40 ER - TY - JOUR AU - Sherman, K. E. PY - 2012 DA - 2012// TI - Therapeutic approach to the treatment-naive patient with hepatitis C virus genotype 1 infection: a step-by-step approach JO - Clin Infect Dis VL - 55 UR - https://doi.org/10.1093/cid/cis628 DO - 10.1093/cid/cis628 ID - Sherman2012 ER - TY - JOUR AU - Younossi, Z. M. AU - Singer, M. E. AU - Mir, H. M. AU - Henry, L. AU - Hunt, S. PY - 2014 DA - 2014// TI - Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients JO - J Hepatol VL - 60 UR - https://doi.org/10.1016/j.jhep.2013.11.009 DO - 10.1016/j.jhep.2013.11.009 ID - Younossi2014 ER - TY - STD TI - Colvin HM, Mitchell AE. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. National Academies Press. 2010. ID - ref43 ER - TY - STD TI - Gilead announces SVR12 rates from three phase 3 studies evaluating a once-daily fixed-dose combination of sofosbuvir and ledipasvir for genotype 1 hepatitis C patients. [http://www.gilead.com/news/press-releases/2013/12/gilead-announces-svr12-rates-from-three-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1-hepatitis-c-patients]. Accessed 7 Jan 2014. UR - http://www.gilead.com/news/press-releases/2013/12/gilead-announces-svr12-rates-from-three-phase-3-studies-evaluating-a-oncedaily-fixeddose-combination-of-sofosbuvir-and-ledipasvir-for-genotype-1-hepatitis-c-patients ID - ref44 ER - TY - STD TI - Sovaldi. Highlights of prescribing information. [http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf]. Accessed 7 Jan 2014. UR - http://www.gilead.com/%7e/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf ID - ref45 ER - TY - STD TI - FastStats. Body measurements. [http://www.cdc.gov/nchs/fastats/bodymeas.htm]. Accessed 10 April 2014. UR - http://www.cdc.gov/nchs/fastats/bodymeas.htm ID - ref46 ER - TY - STD TI - PR Newswire. A significant share of surveyed treatment-naive and prior failure HCV patients plan to initiate an HCV treatment regimen in the next year. PR Newswire. 2013. ID - ref47 ER - TY - JOUR AU - Yee, H. S. AU - Chang, M. F. AU - Pocha, C. AU - Lim, J. AU - Ross, D. AU - Morgan, T. R. AU - Monto, A. PY - 2012 DA - 2012// TI - Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office JO - Am J Gastroenterol VL - 107 UR - https://doi.org/10.1038/ajg.2012.48 DO - 10.1038/ajg.2012.48 ID - Yee2012 ER -